718 WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1818977463308386304 |
|---|---|
| author | Christopher Nirschl Kristin Morris Heather Brodkin Daniel Hicklin Nesreen Ismail Andres Salmeron Philipp Steiner Zoe Steuert Jenna Sullivan William Winston Cindy Seidel-Dugan |
| author_facet | Christopher Nirschl Kristin Morris Heather Brodkin Daniel Hicklin Nesreen Ismail Andres Salmeron Philipp Steiner Zoe Steuert Jenna Sullivan William Winston Cindy Seidel-Dugan |
| author_sort | Christopher Nirschl |
| collection | DOAJ |
| first_indexed | 2024-12-20T16:28:08Z |
| format | Article |
| id | doaj.art-3596c09c2f37405a823df42493709240 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-20T16:28:08Z |
| publishDate | 2021-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-3596c09c2f37405a823df424937092402022-12-21T19:33:19ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-11-019Suppl 210.1136/jitc-2021-SITC2021.718718 WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer modelsChristopher Nirschl0Kristin Morris1Heather Brodkin2Daniel Hicklin3Nesreen Ismail4Andres Salmeron5Philipp Steiner6Zoe Steuert7Jenna Sullivan8William Winston9Cindy Seidel-Dugan10Aff1 grid.38142.3c000000041936754XBrigham and Women`s Hospital, Department of DermatologyHarvard Medical School Boston MA USA1Werewolf Therapeutics, Cambridge, MA, United States1Werewolf Therapeutics, Cambridge, MA, United States1Werewolf Therapeutics, Cambridge, MA, United States1Werewolf Therapeutics, Cambridge, MA, United States1Werewolf Therapeutics, Cambridge, MA, United States1Werewolf Therapeutics, Cambridge, MA, United States1Werewolf Therapeutics, Cambridge, MA, United States2Werewolftx.com, Cambridge, MA, United States1Werewolf Therapeutics, Cambridge, MA, United StatesWerewolf Therapeutics, Cambridge, MA, United States |
| spellingShingle | Christopher Nirschl Kristin Morris Heather Brodkin Daniel Hicklin Nesreen Ismail Andres Salmeron Philipp Steiner Zoe Steuert Jenna Sullivan William Winston Cindy Seidel-Dugan 718 WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models Journal for ImmunoTherapy of Cancer |
| title | 718 WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models |
| title_full | 718 WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models |
| title_fullStr | 718 WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models |
| title_full_unstemmed | 718 WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models |
| title_short | 718 WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models |
| title_sort | 718 wtx 124 is a novel il 2 pro drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models |
| work_keys_str_mv | AT christophernirschl 718wtx124isanovelil2prodrugthatisconditionallyactivatedintumorsanddrivesantitumorimmunityinmurinesyngeneiccancermodels AT kristinmorris 718wtx124isanovelil2prodrugthatisconditionallyactivatedintumorsanddrivesantitumorimmunityinmurinesyngeneiccancermodels AT heatherbrodkin 718wtx124isanovelil2prodrugthatisconditionallyactivatedintumorsanddrivesantitumorimmunityinmurinesyngeneiccancermodels AT danielhicklin 718wtx124isanovelil2prodrugthatisconditionallyactivatedintumorsanddrivesantitumorimmunityinmurinesyngeneiccancermodels AT nesreenismail 718wtx124isanovelil2prodrugthatisconditionallyactivatedintumorsanddrivesantitumorimmunityinmurinesyngeneiccancermodels AT andressalmeron 718wtx124isanovelil2prodrugthatisconditionallyactivatedintumorsanddrivesantitumorimmunityinmurinesyngeneiccancermodels AT philippsteiner 718wtx124isanovelil2prodrugthatisconditionallyactivatedintumorsanddrivesantitumorimmunityinmurinesyngeneiccancermodels AT zoesteuert 718wtx124isanovelil2prodrugthatisconditionallyactivatedintumorsanddrivesantitumorimmunityinmurinesyngeneiccancermodels AT jennasullivan 718wtx124isanovelil2prodrugthatisconditionallyactivatedintumorsanddrivesantitumorimmunityinmurinesyngeneiccancermodels AT williamwinston 718wtx124isanovelil2prodrugthatisconditionallyactivatedintumorsanddrivesantitumorimmunityinmurinesyngeneiccancermodels AT cindyseideldugan 718wtx124isanovelil2prodrugthatisconditionallyactivatedintumorsanddrivesantitumorimmunityinmurinesyngeneiccancermodels |